respiratory syncytial virus subgroup A stabilized prefusion F protein 847A

Respiratory syncytial virus subgroup A stabilized prefusion F protein 847A is a recombinant protein subunit vaccine candidate designed to prevent respiratory syncytial virus (RSV) infection. It consists of the fusion (F) glycoprotein from RSV subgroup A, which has been engineered and stabilized in its prefusion conformation. The prefusion state of the F protein is the primary target for potent neutralizing antibodies, as it contains highly conserved epitopes like Site Ø that are lost when the protein transitions to its postfusion state. This specific construct, designated 847A, was developed by Pfizer and has been evaluated in clinical trials, including pediatric studies coordinated by Fondazione Penta Ets (such as the RSV-Ped-001 trial), to assess safety and immunogenicity. It is typically utilized as a monovalent component or as part of a bivalent vaccine formulation alongside a subgroup B counterpart.

Other names

RSV subgroup A stabilized prefusion F proteinRSV-preF (Subgroup A)